StockNews.com initiated coverage on shares of Pulmatrix (NASDAQ:PULM – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a hold rating on the biotechnology company’s stock.
Pulmatrix Price Performance
Shares of NASDAQ:PULM opened at $2.09 on Tuesday. The stock has a market cap of $7.63 million, a P/E ratio of -0.88 and a beta of 0.99. Pulmatrix has a 1-year low of $1.55 and a 1-year high of $2.75. The firm has a fifty day moving average price of $2.10 and a 200 day moving average price of $1.99.
Pulmatrix (NASDAQ:PULM – Get Free Report) last released its quarterly earnings results on Tuesday, August 13th. The biotechnology company reported ($0.87) earnings per share (EPS) for the quarter. The company had revenue of $1.55 million for the quarter. Pulmatrix had a negative return on equity of 46.86% and a negative net margin of 95.18%.
Pulmatrix Company Profile
Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Recommended Stories
- Five stocks we like better than Pulmatrix
- How to Calculate Return on Investment (ROI)
- When Is the Best Time to Invest in Mutual Funds?
- Breakout Stocks: What They Are and How to Identify Them
- Is NVIDIA Stock in a Correction or Consolidation?
- The Top 3 Healthcare Dividend Stocks to Buy and Hold
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
